Constantly researching new treatments to help people lead vital lives.
Aytu BioPharma is committed to studying new products and treatments to make people’s lives better. Our pipeline and our focus on research are growing.
AR101 (enzastaurin) is a pivotal study-ready therapeutic candidate initially targeting the treatment of vascular Ehlers-Danlos Syndrome (VEDS)
Study being conducted using endotracheal UVA application on COVID-19, to determine safety and efficacy of novel approach to antimicrobial treatment via phototherapy on internal organs.
Microparticle Delivery Technology
Proprietary microparticle delivery technology allows modified-release drug delivery of active pharmaceutical ingredient and has the potential to provide meaningful clinical improvement for a variety of disease states.
NT0502 – Sialorrhea
Product in development for the treatment of Sialorrhea – drooling or excessive salivation as a result of limitations in a person’s ability to control and swallow oral secretions.
Partnering for growth and improving patient health.
Aytu BioPharma is constantly exploring alliances to strengthen our product portfolio. We’re actively seeking to license and/or acquire specialty products and technologies that fit our strategic focus – with an emphasis on products that fulfill unmet needs and improve over existing therapies. We are committed to improving patients’ health worldwide by forging strong partnerships. If you are interested in discussing product opportunities, please contact us today.